Focused On-demand Library for E3 ubiquitin-protein ligase TRAIP

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9BWF2

UPID:

TRAIP_HUMAN

Alternative names:

RING finger protein 206; TRAF-interacting protein

Alternative UPACC:

Q9BWF2; B5BU84; B5BUL3; O00467

Background:

E3 ubiquitin-protein ligase TRAIP, also known as RING finger protein 206 and TRAF-interacting protein, plays a pivotal role in maintaining genome stability under replication stress. It regulates interstrand cross-link repair, controls replication-coupled repair pathways, and is involved in the repair of covalent DNA-protein cross-links. Additionally, TRAIP has a role in spindle assembly checkpoint regulation and acts as a negative regulator of innate immune signaling.

Therapeutic significance:

Given its involvement in Seckel syndrome 9, a disorder characterized by dwarfism, microcephaly, and intellectual disability, targeting E3 ubiquitin-protein ligase TRAIP presents a promising avenue for therapeutic intervention. Understanding the role of this protein could open doors to potential therapeutic strategies.